
Biological Dynamics, Inc. is a molecular diagnostics company specializing in exosome isolation technology to improve global health outcomes by enabling earlier and more accurate disease detection. Their proprietary Verita™ platform, coupled with the ExoVerita™ Pro system, offers a simplified, reliable, and automated workflow for isolating exosomes and extracellular vesicles from various biofluids. This technology aims to provide higher sensitivity for detecting conditions like cancer compared to other methods. The company is actively applying its methods with machine learning for disease detection and operates a CLIA-certified and CAP accredited clinical laboratory. They are advancing oncology research and providing more relevant data for patient care and earlier disease detection.

Biological Dynamics, Inc. is a molecular diagnostics company specializing in exosome isolation technology to improve global health outcomes by enabling earlier and more accurate disease detection. Their proprietary Verita™ platform, coupled with the ExoVerita™ Pro system, offers a simplified, reliable, and automated workflow for isolating exosomes and extracellular vesicles from various biofluids. This technology aims to provide higher sensitivity for detecting conditions like cancer compared to other methods. The company is actively applying its methods with machine learning for disease detection and operates a CLIA-certified and CAP accredited clinical laboratory. They are advancing oncology research and providing more relevant data for patient care and earlier disease detection.
What they do: Automated exosome/extracellular vesicle isolation and multiomic liquid-biopsy assays for earlier disease detection
Flagship products: ExoVerita Pro platform and ExoVita assays (including ExoVita Pancreas LDT)
Clinical operations: Operates a CAP-accredited, CLIA-certified clinical laboratory in San Diego, CA
Founded: 2008–2010 (sources report both 2008 and 2010)
Recent known funding: Multiple rounds including a $26.8M Series C (Nov 2015) and a grant reported Jul 29, 2020; total funding listed as $43,800,000 (USD) on one profile
Early disease detection and molecular diagnostics using exosome/extracellular vesicle isolation and multiomic biomarker assays
2010
Biotechnology
26,800,000
Announced $26.8M Series C financing (company press release)
Latest funding event recorded on profile was a grant announced Jul 29, 2020
“Heritage Group, Alexandria Venture Investment, Irwin Jacobs, Alzheimer's Drug Discovery Foundation, Bill & Melinda Gates Foundation listed among investors/supporters”